Search
Now showing items 1-10 of 17
The evolving management of epithelioid sarcoma.
(2021-07-18)
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.
(ELSEVIER, 2021-06-02)
Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a ...
Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
(MDPI, 2021-06-17)
Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling ...
Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
(FUTURE MEDICINE LTD, 2021-04-21)
Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ...
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
(MDPI, 2021-05-10)
Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in ...
Future Directions in the Treatment of Osteosarcoma.
(MDPI, 2021-01-15)
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy ...
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
(DOVE MEDICAL PRESS LTD, 2021-03-08)
Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ...
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
(NATURE PORTFOLIO, 2021-03-05)
Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised ...
Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.
(ELSEVIER SCIENCE INC, 2021-03-01)
Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients ...
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2021-02-15)
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...